Money Matters: Exit Strategies Revealed: Private Equity or IPO

Explore the potential paths for your startup's future in our 'Exit Strategies Revealed' webinar. Whether considering a public debut with an IPO or seeking the shelter of private equity, this session unveils the options available for your startup's exit strategy. Join us for an in-depth discussion on the considerations, challenges, and advantages of each path, equipping you with the knowledge to make informed decisions for your entrepreneurial journey.  RSVP HERE. 

 _______

Gary Owens serves as the CEO of Mesa Laboratories (NASDAQ: MLAB), a diversified provider of Life Science Tools catering to the biopharmaceutical and clinical genomics segments. With a profound background in strategy, sales & marketing, M&A, company integration, culture building, operations, regulatory compliance, and capital markets, Mr. Owens has successfully led businesses ranging from $40M to $500M in revenue. His prior experience includes roles at Danaher, where he served as Manager, Integration Lead, and played crucial roles in Business Development with Pall, Beckman Coulter Dx, and Beckman Life Sciences. In the early stages of his career, Gary worked with Bain & Company, Trilogy Software, and Accenture, focusing on commercial strategy, commercial execution, and M&A programs.

Gary Owens' technical expertise spans analytics for proteins, cells, genomics, as well as chemical and physical parameters in biopharmaceutical research, development, and bioprocessing, along with clinical diagnostics. His market-level understanding encompasses biotherapeutics based on proteins and emerging modalities in gene therapy, cell therapies, RNA/oligo therapies, peptides, stem cells, ADCs, and more.

Gary Owens holds a BSE in Mechanical Engineering from Tulane University (1990) and earned his Master of Business Administration degree from Columbia Business School in 1994.